Document Detail


Safety, tolerability and pharmacokinetics of a human anti-IL-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.
MedLine Citation:
PMID:  23043368     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
AIMS: Assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of CNTO 5825 following single-dose IV and subcutaneous (SC) administration in healthy and healthy atopic subjects. METHODS: Sixty-four subjects received a single dose of placebo or CNTO 5825 (0.1, 0.3, 1.0, 3.0, or 10 mg/kg IV in a dose-escalating manner, or 3.0 mg/kg SC in healthy subjects; and 10 mg/kg IV in healthy atopic subjects). Subjects were observed for 96 hours post-administration and followed for 16 weeks. Safety and tolerability were monitored and serum samples were collected to measure CNTO 5825 concentrations, antibodies to CNTO 5825, and PD biomarkers. RESULTS: Most adverse events (AEs) were mild-to-moderate in severity and considered unrelated to CNTO 5825 with no dose dependent trends seen. The two serious AEs were considered unrelated to CNTO 5825. After IV administration, CNTO 5825 exhibited linear PK with terminal t1/2 of ∼22-32 days. After a single 3 mg/kg SC dose in healthy subjects, CNTO 5825 was absorbed into the systemic circulation with median tmax of 5.45 days and absolute bioavailability of ∼75%. The PK profile of CNTO 5825 at 10 mg/kg was similar in both healthy and healthy atopic subjects. No antibodies to CNTO 5825 were detected through week 16. In the CNTO 5825-treated healthy atopic subjects, there was a significant reduction in serum IgE and CCL17 (p = 0.028 and 0.068 vs placebo, respectively). CONCLUSIONS: CNTO 5825 was well tolerated, had an acceptable safety profile, exhibited linear PK characteristics and no antibodies to CNTO 5825 were detected.
Authors:
Bart van Hartingsveldt; Ivo P Nnane; Esther Bouman-Thio; Matthew J Loza; Alexa Piantone; Hugh M Davis; Kevin J Petty
Related Documents :
9226738 - Nicotine discrimination and self-administration in humans as a function of smoking status.
2719818 - Behavioral desensitization to nicotine is enhanced differentially by ethanol in long-sl...
7899478 - Adrenocorticotropin release is not involved in the nicotine-induced reversal of hemorrh...
16794568 - Mecamylamine attenuates cue-induced reinstatement of nicotine-seeking behavior in rats.
24509648 - Conversion coefficients for determining organ doses in paediatric spine radiography.
12913798 - The cardiotonic effect of the crude ethanolic extract of nerium oleander in the isolate...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-8
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  -     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 Janssen Research & Development, LLC. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Affiliation:
Immunology Translational Medicine, Janssen Research & Development, LLC, Spring House, PA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The influence of film composition on the morphology, mechanical properties and surfactant recovery o...
Next Document:  Polyethylenimine-Capped Ag Nanoparticle Film as a Platform for Detecting Charged Dye Molecules by Su...